pubmed-article:17627038 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:17627038 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
pubmed-article:17627038 | lifeskim:mentions | umls-concept:C0270736 | lld:lifeskim |
pubmed-article:17627038 | lifeskim:mentions | umls-concept:C1708726 | lld:lifeskim |
pubmed-article:17627038 | lifeskim:mentions | umls-concept:C1413873 | lld:lifeskim |
pubmed-article:17627038 | lifeskim:mentions | umls-concept:C1378702 | lld:lifeskim |
pubmed-article:17627038 | lifeskim:mentions | umls-concept:C0910126 | lld:lifeskim |
pubmed-article:17627038 | lifeskim:mentions | umls-concept:C0392747 | lld:lifeskim |
pubmed-article:17627038 | lifeskim:mentions | umls-concept:C0023746 | lld:lifeskim |
pubmed-article:17627038 | lifeskim:mentions | umls-concept:C0332453 | lld:lifeskim |
pubmed-article:17627038 | pubmed:issue | 2 | lld:pubmed |
pubmed-article:17627038 | pubmed:dateCreated | 2007-7-13 | lld:pubmed |
pubmed-article:17627038 | pubmed:abstractText | To identify low-penetrance genes related to sporadic essential tremor (ET) at the CYP2C locus, located in chromosome 10 q23.33. Leukocytary DNA from 200 ET patients and a control group of 300 unrelated healthy individuals with known CYP2C19 genotypes was studied for common CYP2C8 and CYP2C9 allelic variants by using amplification-restriction analyses. Patients with ET showed the following differences compared with healthy subjects: a 1.6-fold reduction in the frequency for CYP2C8*3 (p=0.006), a 1.35-fold reduction of CYP2C9*2 (p=0.05) and a 1.52-fold reduction in the frequency for CYP2C9*3 (p=0.07). The frequency for patients with ET carrying at least one defective allele was 1.33-fold reduced as compared with healthy subjects (p=0.002). In addition, a disruption of the CYP2C8*3/CYP2C9*2 linkage disequilibrium was observed in ET patients, with a 2.1-fold reduction in the percentage for carriers of the haplotype CYP2C8*3 plus CYP2C9*2 in ET patients (p=0.0001). These findings were independent of gender, age, age of onset, or clinical symptoms. These results suggest that alterations at the CYP2C gene locus are associated with the risk for ET. | lld:pubmed |
pubmed-article:17627038 | pubmed:language | eng | lld:pubmed |
pubmed-article:17627038 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17627038 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:17627038 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17627038 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17627038 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17627038 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17627038 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17627038 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:17627038 | pubmed:issn | 1535-1084 | lld:pubmed |
pubmed-article:17627038 | pubmed:author | pubmed-author:Benito-LeónJu... | lld:pubmed |
pubmed-article:17627038 | pubmed:author | pubmed-author:MartínezCarme... | lld:pubmed |
pubmed-article:17627038 | pubmed:author | pubmed-author:García-Martín... | lld:pubmed |
pubmed-article:17627038 | pubmed:author | pubmed-author:AgúndezJosé... | lld:pubmed |
pubmed-article:17627038 | pubmed:author | pubmed-author:López-Alburqu... | lld:pubmed |
pubmed-article:17627038 | pubmed:author | pubmed-author:Jiménez-Jimén... | lld:pubmed |
pubmed-article:17627038 | pubmed:author | pubmed-author:PuertasInmacu... | lld:pubmed |
pubmed-article:17627038 | pubmed:author | pubmed-author:Alonso-Navarr... | lld:pubmed |
pubmed-article:17627038 | pubmed:author | pubmed-author:García-Ferrer... | lld:pubmed |
pubmed-article:17627038 | pubmed:author | pubmed-author:Vázquez-Torre... | lld:pubmed |
pubmed-article:17627038 | pubmed:author | pubmed-author:ZurdoJosé MJM | lld:pubmed |
pubmed-article:17627038 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:17627038 | pubmed:volume | 9 | lld:pubmed |
pubmed-article:17627038 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:17627038 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:17627038 | pubmed:pagination | 195-204 | lld:pubmed |
pubmed-article:17627038 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
pubmed-article:17627038 | pubmed:meshHeading | pubmed-meshheading:17627038... | lld:pubmed |
pubmed-article:17627038 | pubmed:meshHeading | pubmed-meshheading:17627038... | lld:pubmed |
pubmed-article:17627038 | pubmed:meshHeading | pubmed-meshheading:17627038... | lld:pubmed |
pubmed-article:17627038 | pubmed:meshHeading | pubmed-meshheading:17627038... | lld:pubmed |
pubmed-article:17627038 | pubmed:meshHeading | pubmed-meshheading:17627038... | lld:pubmed |
pubmed-article:17627038 | pubmed:meshHeading | pubmed-meshheading:17627038... | lld:pubmed |
pubmed-article:17627038 | pubmed:meshHeading | pubmed-meshheading:17627038... | lld:pubmed |
pubmed-article:17627038 | pubmed:meshHeading | pubmed-meshheading:17627038... | lld:pubmed |
pubmed-article:17627038 | pubmed:meshHeading | pubmed-meshheading:17627038... | lld:pubmed |
pubmed-article:17627038 | pubmed:meshHeading | pubmed-meshheading:17627038... | lld:pubmed |
pubmed-article:17627038 | pubmed:meshHeading | pubmed-meshheading:17627038... | lld:pubmed |
pubmed-article:17627038 | pubmed:meshHeading | pubmed-meshheading:17627038... | lld:pubmed |
pubmed-article:17627038 | pubmed:meshHeading | pubmed-meshheading:17627038... | lld:pubmed |
pubmed-article:17627038 | pubmed:meshHeading | pubmed-meshheading:17627038... | lld:pubmed |
pubmed-article:17627038 | pubmed:meshHeading | pubmed-meshheading:17627038... | lld:pubmed |
pubmed-article:17627038 | pubmed:meshHeading | pubmed-meshheading:17627038... | lld:pubmed |
pubmed-article:17627038 | pubmed:year | 2007 | lld:pubmed |
pubmed-article:17627038 | pubmed:articleTitle | Changes at the CYP2C locus and disruption of CYP2C8/9 linkage disequilibrium in patients with essential tremor. | lld:pubmed |
pubmed-article:17627038 | pubmed:affiliation | Department of Pharmacology and Psychiatry, Medical School, University of Extremadura, Badajoz, and Department of Medicine-Neurology, Príncipe de Asturias Hospital, Alcalá de Henares, Madrid, Spain. | lld:pubmed |
pubmed-article:17627038 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:17627038 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
entrez-gene:1558 | entrezgene:pubmed | pubmed-article:17627038 | lld:entrezgene |
entrez-gene:1559 | entrezgene:pubmed | pubmed-article:17627038 | lld:entrezgene |
http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:17627038 | lld:entrezgene |
http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:17627038 | lld:entrezgene |
http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:17627038 | lld:entrezgene |
http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:17627038 | lld:entrezgene |
lhgdn:association:30889 | lhgdn:found_in | pubmed-article:17627038 | lld:lhgdn |
lhgdn:association:30900 | lhgdn:found_in | pubmed-article:17627038 | lld:lhgdn |